Updates in NMOSD and MOGAD Diagnosis and Treatment

IF 2.9 4区医学 Q2 CLINICAL NEUROLOGY Neurologic Clinics Pub Date : 2024-02-01 Epub Date: 2023-08-07 DOI:10.1016/j.ncl.2023.06.009

Laura Cacciaguerra MD, PhD , Eoin P. Flanagan MB, BCh

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

NMOSD和MOGAD诊断和治疗的最新进展

水通道蛋白-4- igg阳性视神经脊髓炎谱系障碍(AQP4+NMOSD)和髓鞘-少突胶质细胞糖蛋白抗体相关疾病(MOGAD)分别是针对星形胶质细胞和少突胶质细胞的抗体相关疾病。它们被认为是不同的实体，导致每一种都有自己的诊断标准，需要结合临床、血清学和MRI特征。AQP4+NMOSD与MOGAD急性发作的治疗方法相似。现在有1类证据支持AQP4+NMOSD的攻击预防药物。尽管临床试验正在进行，但MOGAD缺乏经过证实的治疗方法。在这篇综述中，我们将概述AQP4+NMOSD与MOGAD在诊断和治疗方面的异同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neurologic Clinics 医学-临床神经学

CiteScore

5.00

自引率

4.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Targeted toward those in the fields of neurology, family medicine, otolaryngology, and pediatrics, Neurologic Clinics offers a broad view of current practice, as well as the evidence to support it. Published quarterly — in February, May, August, and November — each issue focuses on a single topic neurology, including hearing loss, cholesteatoma, rhinology, anosmia, dysphagia, and pediatric-specific ENT.

期刊最新文献

Contents Placebo Responses in Clinical Trials of Analgesics Placebo Response in Acute and Prophylactic Treatment of Migraine Placebo Responses in Trials of Parkinson’s Disease Placebo Effects in the Treatment of Depression—Implications for the Psychedelic Renaissance